(NYSEMKT: PLX) Protalix Biotherapeutics's forecast annual revenue growth rate of -2.67% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 48.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 15.95%.
Protalix Biotherapeutics's revenue in 2026 is $76,381,000.On average, 3 Wall Street analysts forecast PLX's revenue for 2026 to be $6,371,686,021, with the lowest PLX revenue forecast at $6,159,379,744, and the highest PLX revenue forecast at $6,648,771,898. On average, 3 Wall Street analysts forecast PLX's revenue for 2027 to be $5,618,582,883, with the lowest PLX revenue forecast at $4,894,485,537, and the highest PLX revenue forecast at $6,438,077,054.
In 2027, PLX is forecast to generate $5,497,725,420 in revenue, with the lowest revenue forecast at $4,660,022,058 and the highest revenue forecast at $6,438,077,054.